The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Temozolomide resistance in glioblastoma multiforme
Open accessAbstract
Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily to the over-expression of O 6 -methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been developed for use in experiments designed to define the mechanism of TMZ resistance and the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive TMZ resistant GBM cells have not been systemically compared. This article reviews the characteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell lines. It also summarizes potential treatment options for TMZ resistant GBMs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I. R., Lu, L., Irvin, D., Black, K. L., & Yu, J. S. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-67 · Cited by 1,790
Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,272
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812
Yung, W. K. A., Prados, M. D., Yaya-Tur, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R., Olson, J., Chang, S. M., O'Neill, A. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2762 · Cited by 761
Munoz, J. L., Bliss, S. A., Greco, S. J., Ramkissoon, S. H., Ligon, K. L., & Rameshwar, P. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.60 · Cited by 520
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
Newlands, E., Blackledge, G., Slack, J., Rustin, G., Smith, D., Stuart, N., Quarterman, C., Hoffman, R., Stevens, M., Brampton, M., et al. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.57 · Cited by 488
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
Kitange, G. J., Carlson, B. L., Schroeder, M. A., Grogan, P. T., Lamont, J. D., Decker, P. A., Wu, W., James, C. D., & Sarkaria, J. N. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-090 · Cited by 390
Giannini, C., Sarkaria, J. N., Saito, A., Uhm, J. H., Galanis, E., Carlson, B. L., Schroeder, M. A., & James, C. D. (2005) · Neuro-Oncology · doi:10.1215/s1152851704000821 · Cited by 326
Quinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8417 · Cited by 316
Hermisson, M., Klumpp, A., Wick, W., Wischhusen, J., Nagel, G., Roos, W., Kaina, B., & Weller, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03583.x · Cited by 311
Cohen, M. H., Johnson, J. R., & Pazdur, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0722 · Cited by 282
Ujifuku, K., Mitsutake, N., Takakura, S., Matsuse, M., Saenko, V., Suzuki, K., Hayashi, K., Matsuo, T., Kamada, K., Nagata, I., et al. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.04.013 · Cited by 228
Temozolomide for high grade glioma
Hart, M. G., Garside, R., Rogers, G., Stein, K., & Grant, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007415.pub2 · Cited by 213
STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression
Kohsaka, S., Wang, L., Yachi, K., Mahabir, R., Narita, T., Itoh, T., Tanino, M., Kimura, T., Nishihara, H., & Tanaka, S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0801 · Cited by 199
Oliva, C. R., Nozell, S. E., Diers, A., McClugage, S. G., Sarkaria, J. N., Markert, J. M., Darley-Usmar, V. M., Bailey, S. M., Gillespie, G. Y., Landar, A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.147504 · Cited by 193
Agnihotri, S., Gajadhar, A. S., Ternamian, C., Gorlia, T., Diefes, K. L., Mischel, P. S., Kelly, J., McGown, G., Thorncroft, M., Carlson, B. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59334 · Cited by 172
Koul, D., Fu, J., Shen, R., LaFortune, T. A., Wang, S., Tiao, N., Kim, Y.-W., Liu, J.-L., Ramnarian, D., Yuan, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1558 · Cited by 171
Natsume, A., Ishii, D., Wakabayashi, T., Tsuno, T., Hatano, H., Mizuno, M., & Yoshida, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0036 · Cited by 171
Alonso, M. M., Gomez‐Manzano, C., Bekele, B. N., Yung, W. K. A., & Fueyo-Margareto, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-5312 · Cited by 170
Goellner, E. M., Grimme, B., Brown, A. R., Lin, Y., Wang, X., Sugrue, K. F., Mitchell, L., Trivedi, R. N., Tang, J.-B., & Sobol, R. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3213 · Cited by 161
Munoz, J. L., Rodriguez‐Cruz, V., Greco, S. J., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.111 · Cited by 157
Dresemann, G. P., Weller, M., Rosenthal, M. A., Wedding, U., Wagner, W., Engel, E., Heinrich, B., Mayer‐Steinacker, R., Krarup‐Hansen, A., Fluge, Ø., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9976-3 · Cited by 156
Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide
Kanzawa, T., Bedwell, J. R., Kondo, Y., Kondo, S., & Germano, I. M. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.99.6.1047 · Cited by 155
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells
Hertler, C., Roth, P., Wick, W., Schmidt, N., Florea, A., Silginer, M., Reifenberger, G., & Weller, M. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07781.x · Cited by 144
Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review
Quirt, I. C., Verma, S., Petrella, T. M., et al. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1114 · Cited by 143
Bredel, M., Bredel, C., Juric, D., Durán, G. E., Yu, R., Harsh, G. R., Vogel, H. S., Recht, L. D., Scheck, A. C., & Sikic, B. I. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9405 · Cited by 136
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma
Banelli, B., Carra, E., Barbieri, F., Würth, R., Parodi, F., Pattarozzi, A., Carosio, R., Forlani, A., Allemanni, G., Marubbi, D., et al. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1090063 · Cited by 135
Multifaceted resistance of gliomas to temozolomide.
Bocangel, D., Finkelstein, S. D., Schold, S. C., Bhakat, K. K., MITRA, S. P., & Kokkinakis, D. M. (2002) · PubMed · Cited by 135
Uno, M., Oba‐Shinjo, S. M., Camargo, A. A., de Moura, R. P., de Aguiar, P. H. P., Cabrera, H. N., Begnami, M. F. S., Rosemberg, S., Teixeira, M. J., & Marie, S. K. N. (2011) · Clinics · doi:10.1590/s1807-59322011001000013 · Cited by 134
McFaline‐Figueroa, J. L., Braun, C. J., Stanciu, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3616 · Cited by 131
Ryu, C. H., Yoon, W. S., Park, K. Y., Kim, S. M., Lim, J. Y., Woo, J. S., Jeong, C. H., Hou, Y., & Jeun, S. (2012) · BioMed Research International · doi:10.1155/2012/987495 · Cited by 120
van Nifterik, K. A., van den Berg, J., van der Meide, W. F., Ameziane, N., Wedekind, L. E., Steenbergen, R. D. M., Leenstra, S., Lafleur, M. V. M., Slotman, B. J., Stalpers, L. J. A., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605712 · Cited by 116
Zhang, J., Stevens, M. F. G., Laughton, C. A., Madhusudan, S., & Bradshaw, T. D. (2010) · Oncology · doi:10.1159/000306139 · Cited by 110
Clarke, M. J., Mulligan, E. A., Grogan, P. T., Mladek, A. C., Carlson, B. L., Schroeder, M. A., Curtin, N. J., Lou, Z., Decker, P. A., Wu, W., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0854 · Cited by 96
Blough, M. D., Beauchamp, D. C., Westgate, M. R., Kelly, J. J., & Cairncross, J. G. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0283-9 · Cited by 94
The Medicinal Chemistry of Imidazotetrazine Prodrugs
Moody, C., & Wheelhouse, R. T. (2014) · Pharmaceuticals · doi:10.3390/ph7070797 · Cited by 88
Kanzawa, T., Germano, I. M., Kondo, Y., Ito, H., Kyo, S., & Kondo, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601193 · Cited by 83
Montaldi, A. P., Godoy, P. R. D. V., & Sakamoto‐Hojo, E. T. (2015) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2015.06.001 · Cited by 75
Wang, Y., Zhu, S., Cloughesy, T. F., Liau, L. M., & Mischel, P. S. (2004) · Oncogene · doi:10.1038/sj.onc.1207244 · Cited by 71
Reid, J. M., Stevens, D. C., Rubin, J., & Ames, M. M. (1997) · PubMed · Cited by 66
Hunn, M. K., Bauer, E., Wood, C. E., Gasser, O., Dzhelali, M., Ancelet, L. R., Mester, B., SHARPLES, K. J., Findlay, M. P. N., Hamilton, D. A., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1635-7 · Cited by 64
Nguyen, S. A., Stechishin, O. D. M., Luchman, H. A., Lun, X. Q., Senger, D. L., Robbins, S. M., Cairncross, J. G., & Weiss, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1856 · Cited by 63
Natsume, A., Wakabayashi, T., Ishii, D., Maruta, H., Fujii, M., Shimato, S., Ito, M., & Yoshida, J. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0520-x · Cited by 62
Auger, N., Thillet, J., Wanherdrick, K., Idbaïh, A., Legrier, M., Dutrillaux, B., Sanson, M., & Poupon, M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0428 · Cited by 59
Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics
St‐Cœur, P., Poitras, J., Čuperlović‐Culf, M., Touaibia, M., & Morin, P. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1899-6 · Cited by 48
Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells
LEE, E.-S., Ko, K.-K., Joe, Y. A., Kang, S., & Hong, Y.-K. (2010) · Oncology Letters · doi:10.3892/ol.2010.210 · Cited by 46
Uzzaman, M., Keller, G. M., & Germano, I. M. (2007) · Journal of neurosurgery · doi:10.3171/jns.2007.106.4.646 · Cited by 35
HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A
Lee, S. Y., Liu, S., Mitchell, R. M., Slagle‐Webb, B., Hong, Y., Sheehan, J. M., & Connor, J. R. (2010) · International Journal of Cancer · doi:10.1002/ijc.25888 · Cited by 26
Self-citation
Cited by
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Germano, G., Lamba, S., Rospo, G., Barault, L., Magrì, A., Maione, F., Russo, M., Crisafulli, G., Bartolini, A., Lerda, G., et al. (2017) · Nature · doi:10.1038/nature24673 · Cited by 627
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 398
Tomar, M. S., Kumar, A., Srivastava, C., & Shrivastava, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188616 · Cited by 325
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
JIAPAER, S., FURUTA, T., TANAKA, S., KITABAYASHI, T., & NAKADA, M. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2018-0141 · Cited by 324
The Influence of Cell Cycle Regulation on Chemotherapy
Sun, Y., Liu, Y., Ma, X., & Hu, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136923 · Cited by 290
Metadata
- Authors
- Lee, S. Y.
- Venue
- Genes & Diseases
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 3
- Issue
- 3
- Pages
- 198-210
- ISSN
- 2352-3042 (ISSN-L)
- OpenAlex
- W2392045628
- Cited by
- 1,163
- References
- 49
- FWCI
- 24.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.